Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00593138 · ClinicalTrials.gov registry record · Phase 1

Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate

A Phase 1 study, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 1
Development phase
23
Enrollment target

NCT00593138: Completed Phase 1 study, sponsored by Massachusetts General Hospital.

NCT00593138 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00593138, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 1
Development phase
23 participants
Enrollment target

Study Summary

The objectives of this study are to document the pharmacokinetics of the adequacy of DAT receptor occupancy d-MPH formulation in three doses (20 mg, 30 mg, and 40 mg) using PET scanning with C-11 Altropane as the ligand across a range of times. It has been estimated that MPH is effective when the average CNS DAT occupancy is 50% or greater. Focalin XR has been shown to be clinically effective in an analog classroom as early as 1 hour and as late as 12 hours. Therefore, it is hypothesized that the average DAT occupancy will be adequate (50% or greater) at time periods corresponding to the times of clinical efficacy. The first objective is to examine the onset of action by testing whether average DAT occupancy will be adequate (50% or greater) at 1 hour after dosing for each dose tested (20 mg, 30 mg, 40 mg). The second objective is to test the adequacy of average DAT occupancy in a range of later times for each dose. The times chosen (8, 10 and 12 hours) correspond to times Focalin XR has been shown to be clinically effective in an analogue classroom study. A range of times have been chosen since, while effective at 12 hours, the degree of clinical effectiveness decreased with later time periods. The adequacy of DAT occupancy across this range of time periods will provide important details on the in vivo molecular action of the medicine at periods of critical clinical activity. The third exploratory objective is to examine a time period later then those previously tested with the highest dose. Since the clinical effectiveness of Focalin XR has not been tested out to 14 hours, it is unknown whether it is effective at 14 hours. If Focalin XR were to be effective at 14 hours it would be more likely at the highest dose.

Interventions

  • DRUG dex-methylphenidate

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2006-12
Est. Completion 2009-12
Phase Phase 1

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT00593138

The ClinicalTrials.gov registry entry for NCT00593138 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which dex-methylphenidate is the first listed.

NCT00593138 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00593138 about?

NCT00593138 is a clinical study titled "Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate". The objectives of this study are to document the pharmacokinetics of the adequacy of DAT receptor occupancy d-MPH formulation in three doses (20 mg, 30 mg, and 40 mg) using PET scanning with C-11 Altropane as the ligand across a range of times. It has been estimated that MPH is effective when the av...

What is the current status of trial NCT00593138?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2006-12. Estimated completion is 2009-12.

What interventions are being tested in trial NCT00593138?

The interventions under investigation include: dex-methylphenidate (DRUG).

Who is sponsoring clinical trial NCT00593138?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.